The Institute for Clinical and Economic Review (ICER) said Novartis’ decision to price its recently-approved spinal muscular atrophy (SMA) drug, Zolgensma, at $2.1 million was a “positive outcome.”
The Food and Drug Administration (FDA) approved Zolgensma on Friday, May 24.
According to a press release, the drug’s price falls within the organization’s pricing benchmark.
“Zolgensma is dramatically transforming the lives of families affected by this devastating disease, and given the new efficacy data for the presymptomatic population, the price announced today falls within the upper bound of ICER’s value-based pricing benchmark range,” ICER President Steven Pearson said in a statement. “Insurers were going to cover Zolgensma no matter the price, and Novartis has spoken publicly about considering prices that approached $5 million. It is a positive outcome for patients and the entire health system that Novartis instead chose to price Zolgensma at a level that more fairly aligns with the benefits for these children and their families.”